Superbugs & Superdrugs Conference 2018

SMi Group19 - 20 March 2018, London, UK.
SMi's Superbugs & Superdrugs conference this March will focus on the strategies pharmaceutical companies use to assist the development of new therapeutics & drugs, how to obtain funding for new projects and address why there is a current lack of incentives for researchers working in antimicrobial resistance research and development.

Programme Hightlights

  • Analyse the current status of antimicrobial resistance with industry led insight into current strategies to tackle AMR:
    • Jean-Pierre Paccaud, Director of Business Development at GARDP, Drugs for Neglected Diseases initiative (DNDi)
    • Steve Holden, Medical Adviser, MSD
  • Hear exclusive case studies from a selection of pharmaceutical companies on clinical progress:
    • Conrad Lichtenstein, CSO, Nemesis bioscience
    • David Brown, Managing Director and Founder, Alchemy Biomedical Consulting
  • Learn about regulatory pathways for the registration of new antimicrobial agents:
    • Mair Powell, Senior clinical assessor, MHRA
  • Evaluate the latest incentives and funding solutions to spur drug discovery:
    • Mark Albrecht, Health Scientist, HHS/ASPR/BARDA
    • Adrian Towse, Office of Health Economics
  • Explore the latest novel alternatives to antibiotics currently in development:
    • Ian Henderson, Professor of Microbial Biology, University Of Birmingham
    • Stephen Barat, Head of Pre-Clinical and Early Clinical Development, SCYNEXIS Inc
    • Cara Cassino, Chief Medical Officer, ContraFect

For further information and to register, please visit:
http://www.superbugssuperdrugs.com

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...

Addressing social and cultural drivers of type 2 d…

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and ...

Evidence mounts linking aspirin to lower risk of o…

Taking a low-dose aspirin daily may help women lower their risk of developing ovarian cancer. A new study co-led by Moffitt Cancer Center found that women who reported ta...